Search Results

« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 10 of 15

CRC 13086: A Study of Heat Shock Protein 90 (HSP90) Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-Small Cell Lung Cancer (NSCLC)

The purpose of the study is to evaluate safety and efficacy of AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small...

Howard (Jack) West, M.D.
Swedish Cancer Institute

A Phase 1 Study of the safety and pharmacokinetics of crizotinib in combination with MK-3475 (Pembrolizumab) in patients with untreated advanced ALK-translocated non-small cell lung cancer

The purpose of this study has 2 phases, a Dose Finding Phase will determine the maximum tolerated dose . The Dose Expansion Phase will explore the...

Howard West, MD
Swedish Cancer Institute

A Phase 3, Randomized, Open-Label, Multi-Center, Safety And Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Purpose:  The purpose of this research study is to find out if a drug called nab-paclitaxel (Abraxane®) and best supportive care, when given after...

Howard (Jack) West, M.D.
Swedish Cancer Institute

A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer

The primary efficacy objective of the study is to evaluate the efficacy of 16 cycles of Atezolizumab (MPDL3280A) treatment compared with best...

Howard West, MD
Swedish Cancer Institute

A Phase II Single-arm Trial to Investigate Tepotinib in Stage IIIB/IV Adenocarcinoma of the Lung With MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum-doublet-containing Regimen

This study will look at how effective the study drug (tepotinib) is at stopping the growth and spread of lung cancer that carries a specific...

Howard West, MD
Swedish Cancer Institute

A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer

RATIONALE: Wedge resection or segmentectomy may be less invasive types of surgery than lobectomy for non-small cell lung cancer and may have...

Gary Goodman, M.D.
Swedish Cancer Institute

A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma

This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and...

Gary Goodman, M.D.
Swedish Cancer Institute

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

This phase I/II partially randomized trial studies the side effects and best dose of veliparib when given together with radiation therapy,...

Gary Goodman, M.D.
Swedish Cancer Institute

LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients

This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment decisions of Surgeons when added to standard...

Eric Vallieres, M.D.
Swedish Cancer Institute

Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy

Purpose Part A: Subjects will receive Patritumab or placebo with erlotinib. Progression-free survival will be the primary outcome....

Howard (Jack) West, M.D.
Swedish Cancer Institute
« Previous 12 Next »
Viewing Page 1 of 2 | Showing Results 1 - 10 of 15